Oxford Biomedica PLC

About Oxford Biomedica PLC

Oxford Biomedica PLC is a leading gene and cell therapy company based in the UK, dedicated to developing innovative treatments for serious diseases. With a strong focus on advancing the field of biomedicine, the company specializes in the development of viral vectors for gene delivery, which are crucial for the success of gene therapies.

Founded in 1995, Oxford Biomedica has established itself as a pioneer in the biopharmaceutical industry, leveraging its proprietary LentiVector® platform to create advanced therapies for conditions such as cancer, neurodegenerative diseases, and rare genetic disorders. The company collaborates with various pharmaceutical partners to bring cutting-edge therapies to market, ensuring that patients have access to life-changing treatments.

Oxford Biomedica’s commitment to research and development is evident in its robust pipeline of product candidates, which are currently in various stages of clinical trials. The company aims to address unmet medical needs by harnessing the power of gene therapy to provide long-lasting solutions for patients.

In addition to its therapeutic developments, Oxford Biomedica offers contract development and manufacturing services, providing expertise in the production of viral vectors for other companies in the biopharmaceutical sector. This dual approach not only enhances the company’s revenue streams but also strengthens its position as a leader in the gene therapy landscape.

With a vision to transform the treatment of serious diseases through innovative science, Oxford Biomedica is committed to improving patient outcomes and advancing the field of medicine. The company’s headquarters are located in Oxford, UK, where it continues to expand its capabilities and expertise in gene and cell therapy.

As a publicly traded company, Oxford Biomedica is dedicated to maintaining high standards of corporate governance and transparency, ensuring that stakeholders are informed about its progress and achievements.

In summary, Oxford Biomedica PLC stands at the forefront of gene and cell therapy innovation, driven by a mission to develop transformative therapies that can change lives.